Browse
Submit Data
Databases
API
Help

Dataset Information

21 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

ABSTRACT: RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase II trial is studying the side effects of palonosetron hydrochloride and to see how well it works in preventing nausea and vomiting caused by radiation therapy in patients with primary abdominal cancer.

DISEASE(S): Carcinoid Tumor,Colorectal Cancer,Liver Cancer,Small Intestine Cancer,Nausea,Gallbladder Cancer,Pancreatic Cancer,Extrahepatic Bile Duct Cancer,Anus Neoplasms,Carcinoma Of The Appendix,Gastrointestinal Carcinoid Tumor,Vomiting,Nausea And Vomiting,Colon Cancer,Gastric Cancer,Gallbladder Neoplasms,Bile Duct Neoplasms,Anal Cancer,Pancreatic Neoplasms,Stomach Neoplasms,Intestinal Neoplasms,Cholangiocarcinoma,Primary Peritoneal Cavity Cancer

PROVIDER: 2072434 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Project description:RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.

| 2033103 | ecrin-mdr-crc

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Project description:RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

| 2005380 | ecrin-mdr-crc

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Project description:RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by radiation therapy. PURPOSE: This randomized phase III trial is comparing how well ondansetron works with or without dexamethasone in preventing vomiting in patients with cancer who are receiving radiation therapy to the upper abdomen.

| 2006187 | ecrin-mdr-crc

A randomized, multicenter non-inferiority trial of 1-day versus 3-day dexamethasone in combination with palonosetron for prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

Project description:Interventions: dexamethasone day1-3 plus palonosetron dexamethasone day1 plus palonosetron Primary outcome(s): Percentage of patients with complete response (no vomiting and no rescue medication) during day1-5 after moderately emetogenic chemotherapy Study Design: Parallel Randomized

| 2624800 | ecrin-mdr-crc

Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy

Project description:This is a study to determine how much nausea and or vomiting is caused by irinotecan-based chemotherapy in patients with colorectal cancer. Patients with colorectal cancer scheduled to receive their first cycle of an irinotecan-based chemotherapy regimen are eligible. Any chemotherapy agents administered in combination with irinotecan must have low-minimal potential to cause nausea and or vomiting. Examples of acceptable regimens would be irinotecan in combination with infusional fluorouracil and leucovorin (FOLFRI) with or without bevacizumab and irinotecan in combination with cetuximab. Patients who have received prior non-irinotecan-based chemotherapy are eligible providing they experienced no vomiting and no greater than mild nausea with their prior chemotherapy.

| 2058053 | ecrin-mdr-crc

Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer

Project description:Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC). Little is known about the efficacy of aprepitant when used without dexamethasone. Dexamethasone is widely used to prevent both acute and delayed nausea and vomiting induced by chemotherapy. However, multi-period use of dexamethasone could be associated with side effect, such as hyperglycemia, dyspepsia and insomnia. This randomized phase III trial studies antiemetic therapy with aprepitant and tropisetron to see how well they work compared to dexamethasone plus tropisetron in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX(oxaliplatin, leuvovorin and 5-fluorouracil) chemotherapy.

| 2225674 | ecrin-mdr-crc

A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)

Project description:Interventions: Palonosetron 0.75mg/body Dexamethasone 9.9mg/body Palonosetron 0.75mg/body Primary outcome(s): Complete response rate (overall period) Study Design: Parallel Randomized

| 2628600 | ecrin-mdr-crc

Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin

Project description:RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients’ quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.

| 2059306 | ecrin-mdr-crc

Evaluation of combinational effect of Aprepitant on nausea and vomiting induced by chemotherapy (moderate risk) in patients with Gastric Cancer or Colorectal Cancer

Project description:Interventions: Group A: * 1st course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 9.9 mg i.v. on 1st day, 8 mg p.o. on 2nd day and 3rd day) * 2nd course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 4.95 mg i.v. on 1st day, 4 mg p.o. on 2nd day and 3rd day) plus Aprepitant (125 mg p.o. on 1st day, 80 mg p.o. on 2nd day and 3rd day) Group B: * 1st course: Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 4.95 mg i.v. on 1st day, 4 mg p.o. on 2nd day and 3rd day) plus Aprepitant (125 mg p.o. on 1st day, 80 mg p.o. on 2nd day and 3rd day) * 2nd course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 9.9 mg i.v. on 1st day, 8 mg p.o. on 2nd day and 3rd day) Primary outcome(s): * Frequency of vomiting * Severity of nausea Study Design: Cross-over Randomized

| 2623451 | ecrin-mdr-crc

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.

Project description:Netupitant/palonosetron (NEPA; Akynzeo®), available in oral and intravenous (IV) formulations, is a fixed-dose combination of the neurokinin 1 (NK1) receptor antagonist netupitant (or the prodrug, fosnetupitant, in the IV formulation) and the second-generation serotonin 3 (5-HT3) receptor antagonist palonosetron. Administered as a single dose, (fos)netupitant/palonosetron (in combination with dexamethasone) is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. In clinical trials, (fos)netupitant/palonosetron plus dexamethasone was associated with high complete response rates (no emesis and no rescue medication) in the acute, delayed and overall phases in patients receiving highly or moderately emetogenic chemotherapy, with efficacy maintained over multiple cycles. Further, oral netupitant/palonosetron was found to be superior to palonosetron and non-inferior to aprepitant plus granisetron in preventing CINV in individual trials. Both the oral and IV formulations of the drug combination are well tolerated. The fixed-dose combination is concordant with guideline recommendations and provides a simple and convenient option for prophylaxis against acute and delayed CINV in patients receiving highly or moderately emetogenic chemotherapy.

| S-EPMC8463343 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data